Senolytic compound
Fisetin is a naturally occurring flavonoid (3,3',4',7-tetrahydroxyflavone) found in fruits and vegetables (strawberries, apples, onions) that has gained attention as a senolytic compound — an agent that selectively eliminates senescent ('zombie') cells. Research led by the Mayo Clinic's Robert and Arlene Kogod Center on Aging, particularly the labs of James Kirkland and Tamara Tchkonia, has driven clinical interest in fisetin as a senotherapeutic for age-related diseases. Human clinical trials are ongoing but limited.
Present senolytic research without overstating current clinical evidence. Distinguish between preclinical senolytic findings and limited human trial data. Do not publish dosing protocols or sourcing instructions. Track ongoing clinical trials.
Mayo Clinic researchers conducted a clinical trial of fisetin for COVID-19 in skilled nursing facilities, representing one of the first senolytic trials in the clinical setting (Verdoorn et al., J Am Geriatr Soc, 2021; Kirkland and Tchkonia as senior authors).
A 2024 review characterized fisetin as a senotherapeutic agent with evidence for age-related diseases, noting that while preclinical data is strong, clinical translation remains in early stages (Mech Ageing Dev, 2024).
A Phase II randomized placebo-controlled study (TROFFi) of fisetin to improve physical function in breast cancer survivors was registered in 2026, representing ongoing clinical investigation (Ther Adv Med Oncol, 2026).
Fisetin is available as a dietary supplement but is not FDA-approved as a drug for any indication. Senolytic use involves intermittent high-dose administration, which differs from typical supplement use.
Evidence level: Preclinical
Sources: PubMed / NCBI, PubMed / NCBI
Senolytic effects are well-established in preclinical models. Human senolytic efficacy data is emerging but not yet conclusive. Cite the Mayo Clinic research directly.
Evidence level: Peer reviewed
Sources: PubMed / NCBI, PubMed / NCBI
The COVID-19 nursing home trial and the TROFFi breast cancer trial are key clinical studies. Both come from the Kirkland/Tchkonia lab at Mayo Clinic's Kogod Center on Aging. Results are preliminary.
Evidence level: Community discussion
Sources: PubMed / NCBI, PubMed / NCBI
Track this framing without endorsing it. The 'zombie cell' terminology is a simplification of senescent cell biology. Senolytic dosing in humans is still being investigated in clinical trials.
Source records are stored in the repo and linked from each claim.
5-Amino-1MQ (5-amino-1-methylquinoline) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enz...
Regulatory watchAOD-9604 is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone (hGH) residues 177-191,...
Regulatory watchArgireline (Acetyl Hexapeptide-8, formerly Acetyl Hexapeptide-3) is a synthetic hexapeptide fragment of SNAP-25, a prote...
Evidence reviewBPC-157 is widely discussed online in injury recovery and performance communities, but the public evidence and regulator...
Regulatory watch